Fibroblast Growth Factor (FGF) signaling represents a compelling therapeutic target for Parkinson's disease due to its critical role in dopaminergic neuron survival, neuroprotection, and modulation of neuroinflammation. The FGF family, particularly FGF2 and FGF20, has demonstrated robust neuroprotective effects in preclinical PD models through activation of FGFR receptors that promote neuronal survival via PI3K/Akt and MAPK pathways.
This category catalogs companies developing FGF-based therapies for Parkinson's disease, including:
FGF therapy development faces significant challenges including blood-brain barrier penetration, delivery optimization, and balancing neuroprotective effects against mitogenic potential. Several companies are addressing these challenges through novel engineering approaches and delivery technologies.
The FGF therapy field for Parkinson's disease has evolved through multiple generations:
| Attribute | Value |
|---|---|
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |
| Founded | 2000 |
| Focus | AAV gene therapy |
uniQure has developed a proprietary AAV gene therapy platform with applications in Parkinson's disease. The company has explored FGF delivery through academic collaborations, leveraging their high-capacity AAV5 vector technology for sustained expression of neurotrophic factors in the striatum and substantia nigra.
Technology Platform:
FGF Program:
| Attribute | Value |
|---|---|
| Headquarters | Boston, Massachusetts |
| Ticker | VYGR (NASDAQ) |
| Founded | 2013 |
| Focus | AAV gene therapy for neurological disease |
Voyager Therapeutics is developing next-generation AAV vectors for CNS gene therapy, including programs targeting neurotrophic factor delivery for Parkinson's disease.
Technology Platform:
FGF Program:
| Attribute | Value |
|---|---|
| Headquarters | Research Triangle Park, North Carolina |
| Parent | Pfizer |
| Focus | AAV gene therapy |
AskBio (acquired by Pfizer) has extensive experience in AAV-mediated gene therapy for neurological disorders and has explored FGF delivery approaches.
Technology Platform:
FGF Program:
| Attribute | Value |
|---|---|
| Headquarters | New York, New York |
| Ticker | BMY (NYSE) |
| Focus | Broad neuroscience pipeline |
Bristol Myers Squibb has maintained an interest in growth factor signaling modulation for neurodegenerative diseases, with programs targeting FGFR pathways.
Pipeline:
| Attribute | Value |
|---|---|
| Headquarters | Rahway, New Jersey |
| Ticker | MRK (NYSE) |
| Focus | Neuroscience and immunology |
Merck has explored FGFR kinase inhibitors and agonists for various indications, with potential applications in neuroprotection.
FGF/FGFR Programs:
| Attribute | Value |
|---|---|
| Focus | Protein therapeutics |
FerGene has historically worked on protein-based neurotrophin delivery approaches.
Programs:
Academic and research institutions continue to advance FGF therapy development:
Several companies are exploring combination approaches targeting multiple neurotrophic pathways:
Rationale: FGF signaling interfaces with multiple neuroprotective pathways including GDNF, BDNF, and anti-inflammatory pathways. Combination approaches may provide synergistic benefits.
Companies with combination programs:
| Agent | Company | Phase | NCT | Status |
|---|---|---|---|---|
| AAV-GDNF | Various | Phase 1/2 | NCT04167540 | Active |
| AAV-FGF2 | Academic | Phase 1 | NCT02847590 | Completed |
| FGF20 (SC) | Research | Phase 1 | NCT02450756 | Completed |
| Challenge | Solution | Companies Working |
|---|---|---|
| BBB penetration | AAV-mediated expression, intranasal delivery | uniQure, Voyager |
| Mitogenic risk | FGFR1-selective agonists, engineered variants | Multiple |
| Delivery optimization | Focused ultrasound, convection-enhanced delivery | AskBio, others |
| Sustained expression | Regulated AAV systems, cell-type specificity | All gene therapy companies |
The scientific basis for FGF therapy in Parkinson's disease rests on several key findings:
FGF2 and related ligands protect dopaminergic neurons through:
| Company | Round | Amount | Year |
|---|---|---|---|
| uniQure | Public | $140M | 2024 |
| Voyager | Series C | $100M | 2024 |
| Trefoil | Series B | $55M | 2024 |
| Approach | Advantages | Disadvantages | Companies |
|---|---|---|---|
| FGF | Potent neuroprotection, multiple pathways | BBB penetration, mitogenic concerns | uniQure, Voyager |
| GDNF | Strong dopaminergic specificity | Delivery challenges | uniQure, Roche |
| BDNF | Synaptic plasticity | Limited CNS penetration | Various |
| Small molecule | Oral delivery | Novel mechanism risk | BMS, Merck |